Nexstim Oyj: Directors’ transactions – Karvinen
Company spokespersonst, Helsinki, October 12 2022 at 10 AM (EEST)
Nexstim Plc: Transactions of Directors – Karvinen
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”) announces the transactions of the directors as follows:
Person subject to notification obligation
Name: Mikko Karvinen
Position: CEO
Issuer: Nexstim Oyj
LEI: 743700S7ZI0LNMHZ6Y27
Type of announcement: INITIAL ANNOUNCEMENT
Reference number: 20302/5/4
_________________________________________________
Trade date: 2022-10-10
Place: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI4000506811
Nature of transaction: ORDER
(X) Related to the option program
Payment transaction information
(1): Volume: 8850 Unit price: 2 EUR
Aggregated Transactions
(1): Volume: 8850 Volume-weighted average price: 2 EUR
More information is available on the website www.nexstim.comor by contacting:
Mikko KarvinenMANAGING DIRECTOR
+358 50 326 4101
[email protected]
The company’s certified advisor is Erik Penser Bank.
About Nexstim Plc
Nexstim is a Finnish, globally operating, growth-oriented medical technology company. Our mission is to enable individual and effective diagnostics and treatment for challenging brain diseases and disorders.
Nexstim has developed the world’s leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) and highly advanced 3D navigation that provides precise and personalized targeting of TMS to a specific brain area.
Nexstim’s diagnostics business focuses on the commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA-approved and CE-marked navigated TMS system for pre-surgical mapping of the brain’s speech and motor cortex.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA approved for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE-marked for the treatment of severe depression and chronic neuropathic pain.
Nexstim’s shares are listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
More information can be found at www.nexstim.com